CLONIDINE HYDROCHLORIDE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for clonidine hydrochloride and what is the scope of freedom to operate?
Clonidine hydrochloride
is the generic ingredient in six branded drugs marketed by Am Regent, Fresenius Kabi Usa, Hikma Farmaceutica, Xgen Pharms, Zydus Pharms, Mylan Institutional, Tris Pharma Inc, Actavis Elizabeth, Ajanta Pharma Ltd, Amneal Pharms Ny, Chartwell Rx, Dr Reddys Labs Sa, Endo Operations, Jubilant Generics, Novast Labs, Somerset Theraps Llc, Xiamen Lp Pharm Co, Concordia Pharms Inc, Boehringer Ingelheim, Alembic Pharms Ltd, Am Therap, Aurobindo Pharma Ltd, Chartwell Molecules, Duramed Pharms Barr, Impax Labs, Interpharm, Par Pharm, Prinston Inc, Rising, Sun Pharm Inds Inc, Teva, Trupharma, Unichem, Warner Chilcott, Watson Labs, and Yung Shin Pharm, and is included in fifty-eight NDAs. There are two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.Clonidine hydrochloride has twenty-one patent family members in fourteen countries.
There are thirteen drug master file entries for clonidine hydrochloride. Forty-five suppliers are listed for this compound.
Summary for CLONIDINE HYDROCHLORIDE
International Patents: | 21 |
US Patents: | 2 |
Tradenames: | 6 |
Applicants: | 36 |
NDAs: | 58 |
Drug Master File Entries: | 13 |
Finished Product Suppliers / Packagers: | 45 |
Raw Ingredient (Bulk) Api Vendors: | 96 |
Clinical Trials: | 378 |
Patent Applications: | 2,901 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for CLONIDINE HYDROCHLORIDE |
What excipients (inactive ingredients) are in CLONIDINE HYDROCHLORIDE? | CLONIDINE HYDROCHLORIDE excipients list |
DailyMed Link: | CLONIDINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for CLONIDINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Universidad Simón Bolívar | Phase 3 |
National Cancer Institute, Egypt | N/A |
Sollis Therapeutics, Inc. | Phase 3 |
Pharmacology for CLONIDINE HYDROCHLORIDE
Drug Class | Central alpha-2 Adrenergic Agonist |
Mechanism of Action | Adrenergic alpha2-Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for CLONIDINE HYDROCHLORIDE
Paragraph IV (Patent) Challenges for CLONIDINE HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
KAPVAY | Extended-release Tablets | clonidine hydrochloride | 0.1 mg and 0.2 mg | 022331 | 1 | 2011-03-04 |
US Patents and Regulatory Information for CLONIDINE HYDROCHLORIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Zydus Pharms | CLONIDINE HYDROCHLORIDE | clonidine hydrochloride | INJECTABLE;INJECTION | 202601-002 | Feb 20, 2014 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Teva | CLONIDINE HYDROCHLORIDE | clonidine hydrochloride | TABLET;ORAL | 070659-001 | Jul 8, 1986 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Alembic Pharms Ltd | CLONIDINE HYDROCHLORIDE | clonidine hydrochloride | TABLET;ORAL | 091368-003 | Dec 6, 2011 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Watson Labs | CLONIDINE HYDROCHLORIDE | clonidine hydrochloride | TABLET;ORAL | 070397-001 | Mar 23, 1987 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CLONIDINE HYDROCHLORIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Concordia Pharms Inc | JENLOGA | clonidine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022331-001 | Sep 30, 2009 | ⤷ Sign Up | ⤷ Sign Up |
Concordia Pharms Inc | KAPVAY | clonidine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022331-004 | Sep 28, 2010 | ⤷ Sign Up | ⤷ Sign Up |
Boehringer Ingelheim | CATAPRES | clonidine hydrochloride | TABLET;ORAL | 017407-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
Boehringer Ingelheim | CATAPRES | clonidine hydrochloride | TABLET;ORAL | 017407-003 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CLONIDINE HYDROCHLORIDE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
China | 101400343 | Modified release formulations containing drug-ion exchange resin complexes | ⤷ Sign Up |
Australia | 2007227569 | Modified release formulations containing drug-ion exchange resin complexes | ⤷ Sign Up |
Spain | 2378573 | ⤷ Sign Up | |
Japan | 2009530298 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.